Seres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Key Points

• Seres missed quarterly estimates: the company reported EPS of ($2.08) versus the consensus ($1.88), a $0.20 miss, and revenue of $0.36 million versus $0.41 million expected.
• Shares fell about 6.5% to $7.19 after the release, leaving the stock near its 12‑month low and valuing the company at roughly $69 million (PE ~10.9).
• Analysts and institutions are divided: the stock carries a consensus "Hold" rating with a $14 average price target, while institutional ownership is ~59% and firms like Invesco and Goldman Sachs have recently increased their stakes.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20), FiscalAI reports. The company had revenue of $0.36 million during the quarter, compared to analysts' expectations of $0.41 million.

Seres Therapeutics Trading Down 6.5%

Shares of NASDAQ MCRB traded down $0.50 during trading on Tuesday, reaching $7.19. The company had a trading volume of 44,346 shares, compared to its average volume of 61,730. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $29.98. The stock has a 50-day moving average price of $8.69 and a two-hundred day moving average price of $13.29. The stock has a market capitalization of $69.23 million, a PE ratio of 10.91 and a beta of 0.12.

Analysts Set New Price Targets

A number of research firms have recently commented on MCRB. Wall Street Zen downgraded Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 14th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $22.00 price objective on shares of Seres Therapeutics in a research report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Seres Therapeutics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics presently has an average rating of "Hold" and a consensus price target of $14.00.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds have recently made changes to their positions in the business. Invesco Ltd. boosted its holdings in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 89,995 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 21,679 shares during the last quarter. Marshall Wace LLP acquired a new position in Seres Therapeutics in the second quarter valued at $1,016,000. Vanguard Group Inc. boosted its holdings in Seres Therapeutics by 6.8% in the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company's stock valued at $6,001,000 after acquiring an additional 19,793 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Seres Therapeutics in the third quarter valued at $557,000. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.